[go: up one dir, main page]

MX2023006039A - Celulas inmunes defectuosas para suv39h1. - Google Patents

Celulas inmunes defectuosas para suv39h1.

Info

Publication number
MX2023006039A
MX2023006039A MX2023006039A MX2023006039A MX2023006039A MX 2023006039 A MX2023006039 A MX 2023006039A MX 2023006039 A MX2023006039 A MX 2023006039A MX 2023006039 A MX2023006039 A MX 2023006039A MX 2023006039 A MX2023006039 A MX 2023006039A
Authority
MX
Mexico
Prior art keywords
immune cell
suv39h1
immune cells
cells defective
specifically binds
Prior art date
Application number
MX2023006039A
Other languages
English (en)
Inventor
Eliane Piaggio
Sebastian Amigorena
Christel Goudot
Luigia Pace
Geneviève Almouzni
Leticia Niborski
Original Assignee
Inst Curie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Curie filed Critical Inst Curie
Publication of MX2023006039A publication Critical patent/MX2023006039A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se relaciona con una célula inmune diseñada defectuosa para Suv39h1; preferiblemente, dicha célula inmune diseñada comprende además un receptor de antígeno genéticamente diseñado que se une específicamente a un antígeno objetivo; la presente invención también se refiere a un método para obtener una célula inmune diseñada genéticamente que comprende un paso que consiste en inhibir la expresión y/o actividad de Suv39h1 en la célula inmune; y opcionalmente comprende además un paso que consiste en introducir en dicha célula inmune un receptor de antígeno genéticamente diseñado que se une específicamente a un antígeno objetivo; la invención también abarca dicha célula inmune diseñada para su uso en terapia adoptiva, notablemente para el tratamiento de cáncer.
MX2023006039A 2017-06-20 2019-12-20 Celulas inmunes defectuosas para suv39h1. MX2023006039A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17305757 2017-06-20

Publications (1)

Publication Number Publication Date
MX2023006039A true MX2023006039A (es) 2023-06-02

Family

ID=59295130

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019015841A MX2019015841A (es) 2017-06-20 2018-06-20 Celulas inmunes defectuosas para suv39h1.
MX2023006039A MX2023006039A (es) 2017-06-20 2019-12-20 Celulas inmunes defectuosas para suv39h1.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2019015841A MX2019015841A (es) 2017-06-20 2018-06-20 Celulas inmunes defectuosas para suv39h1.

Country Status (23)

Country Link
US (5) US10576103B2 (es)
EP (2) EP3828264A1 (es)
JP (2) JP7388798B2 (es)
KR (1) KR20200027512A (es)
CN (3) CN114350613B (es)
AU (1) AU2018287042A1 (es)
BR (2) BR112019027133B8 (es)
CA (1) CA3067446A1 (es)
CY (1) CY1124069T1 (es)
DK (1) DK3538645T3 (es)
ES (1) ES2871400T3 (es)
HR (1) HRP20210567T1 (es)
HU (1) HUE053760T2 (es)
IL (1) IL271618B2 (es)
LT (1) LT3538645T (es)
MX (2) MX2019015841A (es)
PL (1) PL3538645T3 (es)
PT (1) PT3538645T (es)
RS (1) RS61691B1 (es)
SG (1) SG11201912455VA (es)
SI (1) SI3538645T1 (es)
SM (1) SMT202100206T1 (es)
WO (1) WO2018234370A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7388798B2 (ja) * 2017-06-20 2023-11-29 アンスティテュート キュリー Ｓｕｖ３９ｈ１を欠損する免疫細胞
EP4003407A1 (en) * 2019-07-23 2022-06-01 Mnemo Therapeutics Immune cells defective for suv39h1
WO2023284721A1 (zh) * 2021-07-13 2023-01-19 苏州沙砾生物科技有限公司 一种免疫细胞的培养方法及其用途
WO2023126458A1 (en) * 2021-12-28 2023-07-06 Mnemo Therapeutics Immune cells with inactivated suv39h1 and modified tcr
EP4463549A2 (en) * 2022-01-14 2024-11-20 Tune Therapeutics, Inc. Compositions, systems, and methods for programming t cell phenotypes through targeted gene repression
CA3249177A1 (en) 2022-01-21 2023-07-27 Inst Curie MODULATION OF SUV39H1 EXPRESSION BY RNA
EP4279085A1 (en) 2022-05-20 2023-11-22 Mnemo Therapeutics Compositions and methods for treating a refractory or relapsed cancer or a chronic infectious disease
WO2024074713A1 (en) 2022-10-07 2024-04-11 Institut National de la Santé et de la Recherche Médicale Method to generate improving car-t cells
CN118995620A (zh) * 2023-05-16 2024-11-22 清华大学 一种嵌合抗原受体、重组免疫细胞及用途
WO2024251200A1 (en) * 2023-06-07 2024-12-12 Fbd Biologics Limited Engineered il-7 variants and methods of use thereof
EP4520334A1 (en) 2023-09-07 2025-03-12 Mnemo Therapeutics Methods and compositions for improving immune response
WO2025052001A1 (en) 2023-09-07 2025-03-13 Mnemo Therapeutics Methods and compositions for improving immune response

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6566A (en) 1849-07-03 Manufacture of bags and sacks
US131A (en) 1837-02-24 Machine foe cutting eur fedm skins
US5049386A (en) 1985-01-07 1991-09-17 Syntex (U.S.A.) Inc. N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4946787A (en) 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
WO1991017424A1 (en) 1990-05-03 1991-11-14 Vical, Inc. Intracellular delivery of biologically active substances by means of self-assembling lipid complexes
US5436150A (en) 1992-04-03 1995-07-25 The Johns Hopkins University Functional domains in flavobacterium okeanokoities (foki) restriction endonuclease
US5487994A (en) 1992-04-03 1996-01-30 The Johns Hopkins University Insertion and deletion mutants of FokI restriction endonuclease
US5356802A (en) 1992-04-03 1994-10-18 The Johns Hopkins University Functional domains in flavobacterium okeanokoites (FokI) restriction endonuclease
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
DE19608753C1 (de) 1996-03-06 1997-06-26 Medigene Gmbh Transduktionssystem und seine Verwendung
WO1997034634A1 (en) 1996-03-20 1997-09-25 Sloan-Kettering Institute For Cancer Research Single chain fv constructs of anti-ganglioside gd2 antibodies
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
US6566131B1 (en) 2000-10-04 2003-05-20 Isis Pharmaceuticals, Inc. Antisense modulation of Smad6 expression
WO2000014257A1 (en) 1998-09-04 2000-03-16 Sloan-Kettering Institute For Cancer Research Fusion receptors specific for prostate-specific membrane antigen and uses thereof
US6410323B1 (en) 1999-08-31 2002-06-25 Isis Pharmaceuticals, Inc. Antisense modulation of human Rho family gene expression
AU2472400A (en) 1998-10-20 2000-05-08 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
US6107091A (en) 1998-12-03 2000-08-22 Isis Pharmaceuticals Inc. Antisense inhibition of G-alpha-16 expression
US5981732A (en) 1998-12-04 1999-11-09 Isis Pharmaceuticals Inc. Antisense modulation of G-alpha-13 expression
US6046321A (en) 1999-04-09 2000-04-04 Isis Pharmaceuticals Inc. Antisense modulation of G-alpha-i1 expression
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
AU2001245793A1 (en) 2000-03-16 2001-09-24 Cold Spring Harbor Laboratory Methods and compositions for rna interference
WO2001094944A2 (en) 2000-06-02 2001-12-13 Memorial Sloan-Kettering Cancer Center Artificial antigen presenting cells and methods of use thereof
US6365354B1 (en) 2000-07-31 2002-04-02 Isis Pharmaceuticals, Inc. Antisense modulation of lysophospholipase I expression
US6566135B1 (en) 2000-10-04 2003-05-20 Isis Pharmaceuticals, Inc. Antisense modulation of caspase 6 expression
EP1334188B1 (en) 2000-11-07 2006-08-30 City of Hope Cd19-specific redirected immune cells
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US20090257994A1 (en) 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
US20050129671A1 (en) 2003-03-11 2005-06-16 City Of Hope Mammalian antigen-presenting T cells and bi-specific T cells
US20050025763A1 (en) 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
CA2555185C (en) 2004-02-06 2020-03-24 Morphosys Ag Anti-cd38 human antibodies and uses therefor
US20090304679A1 (en) 2004-05-27 2009-12-10 Weidanz Jon A Antibodies as T cell receptor mimics, methods of production and uses thereof
EA015584B1 (ru) 2005-03-23 2011-10-31 Генмаб А/С Антитело к cd38 человека и его применение
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
PT2856876T (pt) 2007-03-30 2018-03-28 Memorial Sloan Kettering Cancer Center Expressão constitutiva de ligantes co-estimulatórios em linfócitos t adotivamente transferidos
US8479118B2 (en) 2007-12-10 2013-07-02 Microsoft Corporation Switching search providers within a browser search box
US9221914B2 (en) 2007-12-26 2015-12-29 Biotest Ag Agents targeting CD138 and uses thereof
WO2009126537A1 (en) * 2008-04-07 2009-10-15 Syndax Pharmaceuticals, Inc. Administration of an inhibitor of hdac and an hmt inhibitor
JP5173594B2 (ja) 2008-05-27 2013-04-03 キヤノン株式会社 管理装置、画像形成装置及びそれらの処理方法
TWI580431B (zh) 2008-08-19 2017-05-01 腫瘤療法 科學股份有限公司 Ｈｉｇ２與ｕｒｌｃ１０抗原決定位胜肽以及含此胜肽之疫苗
KR20110096536A (ko) 2008-10-31 2011-08-30 애보트 바이오테라퓨틱스 코포레이션 희귀 림프종의 치료를 위한 항ｃｓ1 항체의 용도
WO2011009173A1 (en) 2009-07-23 2011-01-27 Mater Medical Research Institute Cancer immunotherapy
CA2783351C (en) 2009-12-10 2021-09-07 Regents Of The University Of Minnesota Tal effector-mediated dna modification
CA2798988C (en) 2010-05-17 2020-03-10 Sangamo Biosciences, Inc. Tal-effector (tale) dna-binding polypeptides and uses thereof
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
KR101976882B1 (ko) 2011-03-23 2019-05-09 프레드 헛친슨 켄서 리서치 센터 세포 면역요법용 방법 및 조성물
JP6082997B2 (ja) 2011-04-01 2017-02-22 メモリアル スローン−ケタリング キャンサー センター Ｈｌａ−ａ２により提示されるｗｔ１ペプチドへのｔ細胞受容体様抗体
US8398282B2 (en) 2011-05-12 2013-03-19 Delphi Technologies, Inc. Vehicle front lighting assembly and systems having a variable tint electrowetting element
JP6208667B2 (ja) * 2011-10-03 2017-10-04 ユニベルシテ リブレ デ ブリュッセル 持続的ｈｉｖ感染症を処置するためのｈｉｖ−１遺伝子発現の再活性化
US20150038496A1 (en) * 2011-10-03 2015-02-05 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods and pharmaceutical compositions for the treatment of th2 mediated diseases
JP6368243B2 (ja) 2011-11-11 2018-08-08 フレッド ハッチンソン キャンサー リサーチ センター がんのためのサイクリンａ１に標的化されたｔ細胞免疫療法
JP6850528B2 (ja) 2012-02-13 2021-03-31 シアトル チルドレンズ ホスピタル ドゥーイング ビジネス アズ シアトル チルドレンズ リサーチ インスティテュート 二重特異性キメラ抗原受容体およびその治療的使用
WO2013126726A1 (en) 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Double transgenic t cells comprising a car and a tcr and their methods of use
RU2665548C2 (ru) 2012-05-03 2018-08-30 Фред Хатчинсон Кансэр Рисёч Сентер Способ получения клеток, экспрессирующих т-клеточный рецептор
CA3133545C (en) 2012-05-25 2023-08-08 Cellectis Use of pre t alpha or functional variant thereof for expanding tcr alpha deficient t cells
PL2884999T3 (pl) 2012-08-20 2021-07-05 Fred Hutchinson Cancer Research Center Sposób i kompozycje do immunoterapii komórkowej
US9181535B2 (en) 2012-09-24 2015-11-10 The Chinese University Of Hong Kong Transcription activator-like effector nucleases (TALENs)
RU2729401C2 (ru) 2012-10-02 2020-08-06 Мемориал Слоан-Кеттеринг Кэнсер Сентер Композиции и способы для иммунотерапии
ES2824024T3 (es) 2012-10-10 2021-05-11 Sangamo Therapeutics Inc Compuestos modificadores de células T y usos de los mismos
JP6465803B2 (ja) 2012-10-22 2019-02-06 シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ Ｅｔｐ誘導体
US20140161785A1 (en) * 2012-12-10 2014-06-12 Feiyan Liu Verticillin A Inhibition of Histone Methyltransferases
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
US9405601B2 (en) 2012-12-20 2016-08-02 Mitsubishi Electric Corporation In-vehicle apparatus and program
US9108442B2 (en) 2013-08-20 2015-08-18 Ricoh Company, Ltd. Image forming apparatus
MA42895A (fr) * 2015-07-15 2018-05-23 Juno Therapeutics Inc Cellules modifiées pour thérapie cellulaire adoptive
JP7388798B2 (ja) * 2017-06-20 2023-11-29 アンスティテュート キュリー Ｓｕｖ３９ｈ１を欠損する免疫細胞

Also Published As

Publication number Publication date
LT3538645T (lt) 2021-04-26
CN114350613B (zh) 2024-12-31
BR122020025496B1 (pt) 2023-09-26
CN114058590A (zh) 2022-02-18
RU2020101755A (ru) 2021-07-20
RU2020101755A3 (es) 2021-08-16
CN114350613A (zh) 2022-04-15
MX2019015841A (es) 2020-08-03
DK3538645T3 (da) 2021-04-19
RS61691B1 (sr) 2021-05-31
WO2018234370A1 (en) 2018-12-27
US20230201264A1 (en) 2023-06-29
HRP20210567T1 (hr) 2021-09-03
BR112019027133B1 (pt) 2022-07-19
CN110997902B (zh) 2021-11-30
CY1124069T1 (el) 2022-05-27
ES2871400T8 (es) 2022-03-31
JP2024023299A (ja) 2024-02-21
IL271618B1 (en) 2024-02-01
KR20200027512A (ko) 2020-03-12
IL271618B2 (en) 2024-06-01
IL271618A (en) 2020-02-27
US12371471B2 (en) 2025-07-29
EP3828264A1 (en) 2021-06-02
US20200171090A1 (en) 2020-06-04
US20220040235A1 (en) 2022-02-10
HUE053760T2 (hu) 2021-07-28
EP3538645B1 (en) 2021-01-20
SI3538645T1 (sl) 2021-08-31
SMT202100206T1 (it) 2021-07-12
BR112019027133B8 (pt) 2022-08-09
US11285176B2 (en) 2022-03-29
SG11201912455VA (en) 2020-01-30
PT3538645T (pt) 2021-04-15
BR112019027133A2 (pt) 2020-07-07
JP7706523B2 (ja) 2025-07-11
BR122020025496B8 (pt) 2023-10-24
CA3067446A1 (en) 2018-12-27
CN110997902A (zh) 2020-04-10
EP3538645A1 (en) 2019-09-18
JP7388798B2 (ja) 2023-11-29
PL3538645T3 (pl) 2021-11-08
AU2018287042A1 (en) 2020-02-06
US20250011389A1 (en) 2025-01-09
US10576103B2 (en) 2020-03-03
US11622978B2 (en) 2023-04-11
CN114058590B (zh) 2024-08-06
ES2871400T3 (es) 2021-10-28
US20190365807A1 (en) 2019-12-05
JP2020523995A (ja) 2020-08-13

Similar Documents

Publication Publication Date Title
MX2023006039A (es) Celulas inmunes defectuosas para suv39h1.
SA519401522B1 (ar) Lag-3 أجـسـام مـضـادة لـ وتـركـيـبـات
MX2017002205A (es) Receptor quimerico de antigeno (car) anti-cd123 para uso en el tratamiento de cancer.
BR112018070636A2 (pt) método de tratamento de um sujeito humano que tem câncer, anticorpo, uso de um anticorpo, anticorpo para uso, combinação de um anticorpo, kit para uso no tratamento de câncer, composição farmacêutica, anticorpo biespecífico, método para tratamento de câncer, anticorpo biespecífico para uso e método de depleção de células t reguladoras em um tumor sólido em um sujeito
AR104809A1 (es) Anticuerpos anti-cd40 y usos de los mismos
MX2016006726A (es) Composiciones que comprenden anticuerpos anti-molecula de adhesion celular relacionada con antigeno carcinoembrionario 1 y anti-muerte celular programada para la terapia contra el cancer.
DOP2020000020A (es) Anticuerpos anti-cd137
MX2015010836A (es) Tratamiento de cancer utilizando un receptor quimerico de antigeno anti egfrviii humanizado.
EA201691866A1 (ru) Проникающие в опухоль лимфоциты для адоптивной клеточной терапии
BR112017008914A2 (pt) método para tratar câncer, composição e uso da composição
PH12014501122A1 (en) Methods of treatment using an antibody against interferon gamma
DOP2015000108A (es) Compuestos de pirrolopirimidina como inhibidores de quinasas
UY35468A (es) Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
WO2015011282A3 (en) Method for identifying modulators of bcrp/abcg2-mediated atp release and use of said modulators for treating diseases
MY198289A (en) Pharmaceutical Composition for use in a Method of Removing Immune Suppression in a Tumor Microenvironment or Stimulating an Immune System Against Cancer Cells
AR103726A1 (es) Cristales de anticuerpos monoclonales anti-pd-1 humanos
BR112016020009A2 (pt) anticorpo, composição farmacêutica, método para inibir a proliferação de células cancerígenas, hibridoma
MX2020004837A (es) Inhibidores de la vía de adenosina para el tratamiento del cáncer.
BR112018006140A2 (pt) anticorpo ou uma porção de ligação a antígeno do mesmo, composição farmacêutica, e, método para inibição de proliferação de células cancerígenas.
MX2018006249A (es) Nuevos anticuerpos anti-emr2 y metodos de uso.
MX2017012867A (es) Composiciones terapeuticas y metodos de uso para tratar el cancer.
MX2019012465A (es) Terapia combinada con un conjugado de anticuerpo y farmaco anti-cd25.
MX2022007833A (es) Nuevos receptores de antigenos quimericos (car) especificos de mesotelina para inmunoterapia de cancer de tumores solidos.
MX2019004940A (es) Uso de beta-catenina como un biomarcador para el tratamiento de canceres que usan el anticuerpo anti-dkk-1.
EA201992431A1 (ru) Комбинированная иммунотерапия рака с использованием пента-аза-макроциклического кольцевого комплекса